Get started
Kuros Bioscience Ltd.Kuros Bioscience Ltd.Kuros Bioscience Ltd.

Kuros Bioscience Ltd.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

CSBTF chart


Full chart

CSBTF upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.10 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.27 USD
Net income (FY)
‪−16.30 M‬ USD
Revenue (FY)
‪39.87 M‬ USD
Shares float
‪24.77 M‬
Beta (1Y)
0.88

Employees


Employees (FY)
5
Change (1Y)
−1 −16.67%
Revenue / Employee (1Y)
‪7.97 M‬ USD
Net income / Employee (1Y)
‪−3.26 M‬ USD

About KUROS N


Sector
Health Technology
Industry
Biotechnology
CEO
Christopher T. Fair
Website
kurosbio.com
Headquarters
Schlieren
Founded
2000
ISIN
CH0325814116
FIGI
BBG000FSKJD3
Kuros Biosciences Ltd. operates as biopharmaceutical company, which engages in developing products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals, and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment offers Fibrin-PTH, a drug-biologic combination which promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and by increasing the lifespan of bone-forming cells. The Legacy portfolio segment is involved in all other products that do not belong to the group's core business strategy. The company was founded by Didier Cowling in 2000 and is headquartered in Schlieren, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

CSBTF news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CSBTF is 30.29 USD — it has increased by 4.45% in the past 24 hours. Watch Kuros Bioscience Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Kuros Bioscience Ltd. stocks are traded under the ticker CSBTF.
CSBTF stock has risen by 4.45% compared to the previous week, the month change is a 37.68% rise, over the last year Kuros Bioscience Ltd. has showed a ‪1.11 K‬% increase.
We've gathered analysts' opinions on Kuros Bioscience Ltd. future price: according to them, CSBTF price has a max estimate of 22.35 USD and a min estimate of 22.35 USD. Watch CSBTF chart and read a more detailed Kuros Bioscience Ltd. stock forecast: see what analysts think of Kuros Bioscience Ltd. and suggest that you do with its stocks.
CSBTF reached its all-time high on Apr 27, 2007 with the price of 142.00 USD, and its all-time low was 0.16 USD and was reached on Apr 14, 2014. View more price dynamics on CSBTF chart.
See other stocks reaching their highest and lowest prices.
CSBTF stock is 6.60% volatile and has beta coefficient of 0.88. Track Kuros Bioscience Ltd. stock price on the chart and check out the list of the most volatile stocks — is Kuros Bioscience Ltd. there?
Today Kuros Bioscience Ltd. has the market capitalization of ‪1.18 B‬, it has increased by 3.63% over the last week.
Yes, you can track Kuros Bioscience Ltd. financials in yearly and quarterly reports right on TradingView.
Kuros Bioscience Ltd. is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
Kuros Bioscience Ltd. revenue for the last half-year amounts to ‪35.37 M‬ USD, despite the estimated figure of ‪33.37 M‬ USD. In the next half-year revenue is expected to reach ‪52.40 M‬ USD.
CSBTF net income for the last half-year is ‪−234.69 K‬ USD, while the previous report showed ‪−10.30 M‬ USD of net income which accounts for 97.72% change. Track more Kuros Bioscience Ltd. financial stats to get the full picture.
No, CSBTF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has 5.00 employees. See our rating of the largest employees — is Kuros Bioscience Ltd. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Kuros Bioscience Ltd. EBITDA is ‪−2.56 M‬ USD, and current EBITDA margin is −18.33%. See more stats in Kuros Bioscience Ltd. financial statements.
Like other stocks, CSBTF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kuros Bioscience Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kuros Bioscience Ltd. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kuros Bioscience Ltd. stock shows the buy signal. See more of Kuros Bioscience Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.